Supraventricular Tacchycardia
MedEducation Flix – SVT & ECG Case-Based Self-Assessment (31 Questions)
Q1. What does this ECG show?

This ECG demonstrates **supraventricular tachycardia (SVT)**. It is characterized by a narrow-complex regular rhythm, typically >150 bpm, with absent or retrograde P waves. The clinical context and abrupt onset/termination help distinguish it from sinus tachycardia.
Q2. What is the most common mechanism of paroxysmal supraventricular tachycardia (PSVT)?
The most common mechanism is AV nodal reentrant tachycardia (AVNRT), caused by dual AV nodal pathways creating a reentrant circuit.
Q3. How does AVRT differ from AVNRT?
AVRT (atrioventricular reentrant tachycardia) involves an accessory pathway (e.g., in Wolff-Parkinson-White syndrome) connecting the atria and ventricles, whereas AVNRT is confined to the AV node.
Q4. What is the characteristic ECG feature of orthodromic AVRT?
A narrow QRS tachycardia with a short RP interval and retrograde P waves, often seen after the QRS complex.
Q5. What are the typical symptoms of SVT?
Palpitations, dizziness, chest discomfort, dyspnea, and occasionally syncope, often with sudden onset and termination.
Q6. What physical maneuvers can terminate AVNRT?
Vagal maneuvers such as Valsalva, carotid sinus massage, and facial immersion in cold water can increase vagal tone and terminate AVNRT.
Q7. When is adenosine indicated in SVT?
Adenosine is first-line pharmacologic treatment for acute termination of narrow-complex SVT (especially AVNRT and AVRT) if vagal maneuvers fail.
Q8. What precautions must be taken before administering adenosine?
Ensure the rhythm is not atrial fibrillation with an accessory pathway, as adenosine may precipitate ventricular fibrillation. Also monitor for bronchospasm in asthmatics.
Q9. What is the usual dose of adenosine for SVT?
Start with 6 mg rapid IV push followed by saline flush; if ineffective, escalate to 12 mg. A second 12 mg dose can be used if needed.
Q10. What are the common side effects of adenosine?
Flushing, chest discomfort, dyspnea, transient AV block, and a brief feeling of doom, all resolving quickly due to its short half-life.
Q11. What are alternative drugs to adenosine in stable SVT?
Verapamil or diltiazem are effective calcium channel blockers, particularly in patients with bronchospasm or adenosine intolerance.
Q12. How can SVT be distinguished from sinus tachycardia?
SVT often has abrupt onset/termination and a fixed rate (usually >150 bpm), whereas sinus tachycardia has a gradual onset and rate variation with activity.
Q13. When is synchronized cardioversion indicated in SVT?
If the patient is hemodynamically unstable, has chest pain, hypotension, or altered mental status, or if pharmacologic measures fail.
Q14. What is the typical energy used for synchronized cardioversion in SVT?
50–100 J is generally effective for narrow-complex tachycardias.
Q15. How is SVT diagnosed on ECG?
Regular narrow-complex tachycardia with absent or retrograde P waves; RP interval can help differentiate subtypes.
Q16. What is the long-term treatment for recurrent AVNRT?
Catheter ablation of the slow AV nodal pathway is highly effective (>95%) and is preferred over long-term medical therapy.
Q17. What is WPW syndrome?
Wolff-Parkinson-White syndrome involves a congenital accessory pathway (Bundle of Kent) causing pre-excitation and a risk of AVRT or pre-excited AF.
Q18. What is the ECG finding of WPW in sinus rhythm?
Short PR interval, delta wave (slurred QRS upstroke), and widened QRS complex.
Q19. Why is verapamil contraindicated in pre-excited AF?
It can block AV nodal conduction, increasing conduction through the accessory pathway and precipitating VF.
Q20. What is the preferred acute management of pre-excited AF?
Use procainamide or flecainide (if no structural heart disease); avoid AV nodal blockers. If unstable, perform synchronized cardioversion.
Q21. How can atrial tachycardia be differentiated from AVNRT or AVRT?
Atrial tachycardia originates from a single ectopic atrial focus and often shows a warm-up and cool-down pattern; P waves are often visible and dissociated from QRS.
Q22. What is multifocal atrial tachycardia (MAT)?
An irregularly irregular rhythm with ≥3 different P wave morphologies, often associated with COPD and hypoxia.
Q23. What is the treatment for MAT?
Correct underlying causes (e.g., hypoxia, electrolyte imbalance). Use rate control with beta-blockers or calcium channel blockers; avoid antiarrhythmics.
Q24. What conditions increase the risk of SVT recurrence?
Structural heart disease, hyperthyroidism, electrolyte imbalance, stimulant use (e.g., caffeine, cocaine), and pregnancy.
Q25. How can SVT present in pregnancy and how is it managed?
Pregnancy increases SVT risk due to hormonal and volume changes. Manage conservatively with vagal maneuvers, adenosine, and avoid teratogenic drugs. Consider ablation postpartum.
Q26. What is junctional tachycardia and when does it occur?
An automatic focus from the AV junction, often post-surgery or drug-induced. ECG shows narrow QRS and inverted P waves in II, III, aVF if visible.
Q27. When is electrophysiologic study indicated in SVT?
To confirm diagnosis, identify the circuit, and perform ablation in recurrent or drug-refractory SVT cases.
Q28. What are the risks of catheter ablation for SVT?
Risk of AV block requiring pacemaker (<1%), vascular complications, pericardial effusion, and rare stroke or infection.
Q29. What lifestyle advice helps reduce SVT recurrence?
Avoid stimulants (caffeine, energy drinks), manage stress, ensure adequate sleep, and correct underlying medical conditions.
Q30. What is the role of wearable ECG monitors in SVT diagnosis?
Useful in capturing intermittent episodes, particularly in palpitations with unclear cause. Devices include Holter monitors and patch ECGs.
Q31. Why is the RP interval important in diagnosing SVT subtype?
Short RP (<70 ms) suggests AVNRT; long RP (>70 ms) favors AVRT or atrial tachycardia. Helps distinguish reentrant from focal mechanisms.